Back to top
more

Corcept Therapeutics (CORT)

(Delayed Data from NSDQ)

$47.62 USD

47.62
1,462,070

-1.35 (-2.76%)

Updated Nov 1, 2024 03:59 PM ET

After-Market: $47.70 +0.08 (0.17%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Corcept (CORT) Surges 5.1%: Is This an Indication of Further Gains?

by Zacks Equity Research

Corcept (CORT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Corcept (CORT) Falls on Loss of Korlym Patent Lawsuit to Teva

by Zacks Equity Research

The United States district court for the district of New Jersey rules against Corcept (CORT) in a patent infringement lawsuit against Teva Pharmaceuticals. Stock declines.

Here's Why Corcept Therapeutics (CORT) is a Strong Momentum Stock

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Nektar (NKTR) Up 4% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Corcept (CORT) Up 0.7% Since Last Earnings Report?

by Zacks Equity Research

Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Corcept (CORT) Beats on Q3 Earnings, Raises '23 Sales View

by Zacks Equity Research

Corcept's (CORT) third-quarter 2023 earnings and revenues surpass estimates. The company raises the full-year revenue guidance for 2023.

Why Earnings Season Could Be Great for Corcept Therapeutics (CORT)

by Zacks Equity Research

Corcept Therapeutics (CORT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Corcept Therapeutics (CORT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Corcept (CORT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CHMP Endorses Merck's (MRK) Keytruda Expansion in Gastric Cancer

by Zacks Equity Research

If approved, Merck's (MRK) Keytruda will be approved for a second indication in advanced gastric or GEJ cancer.

Revolution Medicines, Inc. (RVMD) Soars 23.6%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Revolution Medicines, Inc. (RVMD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

The Zacks Analyst Blog Highlights Pfizer, Allogene Therapeutics and Corcept Therapeutics

by Zacks Equity Research

Pfizer, Allogene Therapeutics and Corcept Therapeutics are included in this Analyst Blog.

Abhinab Dasgupta headshot

Beat the Market the Zacks Way: Novo Nordisk, MakeMyTrip, Fastenal in Focus

by Abhinab Dasgupta

Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.

FDA Approves Pfizer's (PFE) Braftovi + Mektovi for Lung Cancer

by Zacks Equity Research

Pfizer's (PFE) Braftovi + Mektovi drug combo gets label expansion for BRAF V600E-mutant non-small cell lung cancer.

Eli Lilly's (LLY) Mirikizumab Meets Crohn's Disease Study Goals

by Zacks Equity Research

Based on this data, Eli Lilly (LLY) will initiate regulatory submissions worldwide next year seeking regulatory approval for mirikizumab in Crohn's disease.

AbbVie's (ABBV) Rinvoq Meets Key Goal in Phase II Vitiligo Study

by Zacks Equity Research

AbbVie (ABBV) meets the primary goal in the phase II study evaluating Rinvoq in the treatment of adult patients with non-segmental vitiligo.

Amgen's (AMGN) Stock Rallies Almost 5% on Broker Upgrade

by Zacks Equity Research

A Leerink Partner analyst expects accelerating pipeline news flow for Amgen (AMGN).

Incyte (INCY) Posts Upbeat Data From Phase II Vitiligo Study

by Zacks Equity Research

Incyte (INCY) announces new positive 52-week data from its mid-stage study of povorcitinib for the treatment of adult patients with extensive nonsegmental vitiligo.

PHIO Jumps 91% on Encouraging Preclinical Cancer Drug Data

by Zacks Equity Research

Data from preclinical studies show that Phio's (PHIO) cancer drug PH-894 is effective in BRD4 inhibition for treating various cancer indications like melanoma, breast cancer and lung cancer.

Tempest (TPST) Up as First-Line Liver Cancer Study Meets Goals

by Zacks Equity Research

Tempest (TPST) skyrockets 2879% on positive new and updated findings from its early-mid-stage study evaluating TPST-1120 in combination with standard-of-care therapies to treat liver cancer.

Merck's (MRK) Keytruda Early-Stage NSCLC Study Shows OS Benefit

by Zacks Equity Research

Merck's (MRK) phase III study on Keytruda shows a statistically significant overall survival benefit for patients with stage II, IIIA or IIIB NSCLC.

Novo Nordisk (NVO) Up on Positive Kidney Outcomes Study Update

by Zacks Equity Research

Novo Nordisk (NVO) is set to stop its kidney outcomes study on Ozempic based on interim analysis results that met certain pre-specified efficacy criteria for early closure. The stock rises 5.2%.

Alnylam (ALNY) Receives CRL for the Label Expansion of Onpattro

by Zacks Equity Research

Alnylam's (ALNY) label expansion-seeking application for Onpattro, to treat transthyretin-mediated amyloidosis with cardiomyopathy, gets the FDA's CRL on the grounds of insufficient data. The stock falls 5%.

Jasper (JSPR) Up on FDA Nod to Begin Early-Stage Urticaria Study

by Zacks Equity Research

Jasper (JSPR) announces the FDA clearance to begin the clinical study of briquilimab for chronic spontaneous urticaria. The stock of the company rises 16%.

J&J (JNJ) Seeks EU Nod for Rybrevant for First-Line NSCLC

by Zacks Equity Research

J&J (JNJ) files an application in Europe seeking expanded approval for Rybrevant as a first-line combination treatment in patients with advanced or metastatic EGFR exon 20 insertion mutation-positive NSCLC.

Arcutis (ARQT) Up on FDA Nod for Zoryve Label Expansion

by Zacks Equity Research

Arcutis (ARQT) gains on receiving FDA approval for label expansion of Zoryve (roflumilast) cream 0.3% to treat patients in the age group of 6-11 years with plaque psoriasis.